肽和拟肽作为治疗新冠肺炎的药物。
Peptides and peptidomimetics as therapeutic agents for Covid-19.
作者信息
Dahal Achyut, Sonju Jafrin Jobayer, Kousoulas Konstantin G, Jois Seetharama D
机构信息
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy University of Louisiana at Monroe Monroe Louisiana USA.
Department of Pathobiological Sciences, School of Veterinary Medicine Louisiana State University Baton Rouge Louisiana USA.
出版信息
Pept Sci (Hoboken). 2022 Jan;114(1):e24245. doi: 10.1002/pep2.24245. Epub 2021 Oct 11.
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Covid-19 pandemic has caused high morbidity and mortality rates worldwide. Virus entry into cells can be blocked using several strategies, including inhibition of protein-protein interactions (PPIs) between the viral spike glycoprotein and cellular receptors, as well as blocking of spike protein conformational changes that are required for cleavage/activation and fusogenicity. The spike-mediated viral attachment and entry into cells via fusion of the viral envelope with cellular membranes involve PPIs mediated by short peptide fragments exhibiting particular secondary structures. Thus, peptides that can inhibit these PPIs may be used as potential antiviral agents preventing virus entry and spread. This review is focused on peptides and peptidomimetics as PPI modulators and protease inhibitors against SARS-CoV-2.
摘要
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的新冠疫情在全球范围内导致了高发病率和死亡率。可以通过多种策略来阻断病毒进入细胞，包括抑制病毒刺突糖蛋白与细胞受体之间的蛋白质-蛋白质相互作用（PPI），以及阻断刺突蛋白在裂解/激活和融合能力方面所需的构象变化。刺突介导的病毒通过病毒包膜与细胞膜融合而附着并进入细胞，这涉及由具有特定二级结构的短肽片段介导的PPI。因此，能够抑制这些PPI的肽可作为潜在的抗病毒药物来阻止病毒的进入和传播。本综述聚焦于作为PPI调节剂和针对SARS-CoV-2的蛋白酶抑制剂的肽和肽模拟物。
相似文献
1
Peptides and peptidomimetics as therapeutic agents for Covid-19.肽和拟肽作为治疗新冠肺炎的药物。
Pept Sci (Hoboken). 2022 Jan;114(1):e24245. doi: 10.1002/pep2.24245. Epub 2021 Oct 11.
2
Inhibition of Coronavirus Entry and by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.脂肽抑制新型冠状病毒和严重急性呼吸综合征冠状病毒进入宿主细胞
mBio. 2020 Oct 20;11(5):e01935-20. doi: 10.1128/mBio.01935-20.
3
The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.奈非那韦甲磺酸盐（Viracept）是一种强效的 SARS-CoV-2 刺突（S）糖蛋白介导的细胞融合抑制剂，有必要进一步评估其作为抗 COVID-19 感染的抗病毒药物。
J Med Virol. 2020 Oct;92(10):2087-2095. doi: 10.1002/jmv.25985. Epub 2020 May 17.
4
The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.整联蛋白 ZMPSTE24 可保护细胞免受 SARS-CoV-2 刺突介导的假病毒感染和合胞体形成。
mBio. 2022 Oct 26;13(5):e0254322. doi: 10.1128/mbio.02543-22. Epub 2022 Oct 5.
5
Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.冠状病毒刺突的小分子抑制剂：作为 SARS-CoV-2 病毒附着和进入的 ACE2 蛋白-蛋白相互作用抑制剂。
ACS Infect Dis. 2021 Jun 11;7(6):1519-1534. doi: 10.1021/acsinfecdis.1c00070. Epub 2021 May 12.
6
Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.支持将肽和拟肽用作潜在 SARS-CoV-2（COVID-19）治疗药物的证据。
Future Med Chem. 2020 Sep;12(18):1647-1656. doi: 10.4155/fmc-2020-0180. Epub 2020 Jul 16.
7
Genome-wide bioinformatics analysis of human protease capacity for proteolytic cleavage of the SARS-CoV-2 spike glycoprotein.对人类蛋白酶对 SARS-CoV-2 刺突糖蛋白进行蛋白水解切割的能力进行全基因组生物信息学分析。
Microbiol Spectr. 2024 Feb 6;12(2):e0353023. doi: 10.1128/spectrum.03530-23. Epub 2024 Jan 8.
8
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).通过中断严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与血管紧张素转换酶2（ACE2）之间的相互作用来实现SARS-CoV-2早期进入的潜在治疗方法。
Biochem Pharmacol. 2021 Oct;192:114724. doi: 10.1016/j.bcp.2021.114724. Epub 2021 Aug 8.
9
Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.钙蛋白酶-2通过调节血管紧张素转换酶2（ACE2）水平介导严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的进入。
mBio. 2024 Mar 13;15(3):e0228723. doi: 10.1128/mbio.02287-23. Epub 2024 Feb 13.
10
Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.针对 SARS-CoV-2 细胞进入机制的靶向治疗策略：体外和体内研究的系统评价。
J Cell Physiol. 2021 Apr;236(4):2364-2392. doi: 10.1002/jcp.30032. Epub 2020 Sep 9.
引用本文的文献
1
Peptide Inhibitor Assay for Allocating Functionally Important Accessible Sites Throughout a Protein Chain: Restriction Endonuclease EcoRI as a Model Protein System.用于在整个蛋白质链中定位功能重要可及位点的肽抑制剂分析：限制性内切核酸酶EcoRI作为模型蛋白质系统
BioTech (Basel). 2024 Dec 30;14(1):1. doi: 10.3390/biotech14010001.
2
Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2).基于肽的蛋白质-蛋白质相互作用（PPI）抑制剂：以严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与人血管紧张素转换酶2（hACE2）之间的相互作用为例
Biomedicines. 2024 Oct 16;12(10):2361. doi: 10.3390/biomedicines12102361.
3
A Multi-Faceted Binding Assessment of Aptamers Targeting the SARS-CoV-2 Spike Protein.针对 SARS-CoV-2 刺突蛋白的适体的多方面结合评估。
Int J Mol Sci. 2024 Apr 24;25(9):4642. doi: 10.3390/ijms25094642.
4
A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection.一种用于快速发现针对 SARS-CoV-2 假病毒感染的肽抑制剂的综合技术平台。
Int J Mol Sci. 2023 Jul 29;24(15):12146. doi: 10.3390/ijms241512146.
5
A lysine-based 2:1-[α/aza]-pseudopeptide series used as additives in polymeric membranes for CO capture: synthesis, structural studies, and application.一种基于赖氨酸的2:1-[α/氮杂]-拟肽系列，用作聚合物膜中CO捕获的添加剂：合成、结构研究及应用。
RSC Adv. 2023 Mar 29;13(15):10051-10067. doi: 10.1039/d3ra00409k. eCollection 2023 Mar 27.
6
Dimerized fusion inhibitor peptides targeting the HR1-HR2 interaction of SARS-CoV-2.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）HR1-HR2相互作用的二聚化融合抑制剂肽
RSC Adv. 2023 Mar 20;13(13):8779-8793. doi: 10.1039/d2ra07356k. eCollection 2023 Mar 14.
7
Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches.通过计算方法设计针对ACE2 SARS-CoV-2刺突结合区域的新型干扰肽。
Front Pharmacol. 2022 Nov 11;13:996005. doi: 10.3389/fphar.2022.996005. eCollection 2022.
8
Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2.基于天然结构的肽作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与人血管紧张素转换酶2（ACE2）蛋白质-蛋白质相互作用的高效抑制剂的改进。
Front Mol Biosci. 2022 Sep 28;9:983014. doi: 10.3389/fmolb.2022.983014. eCollection 2022.
本文引用的文献
1
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.药物诱导的磷脂沉积症使 SARS-CoV-2 的药物再利用变得复杂。
Science. 2021 Jul 30;373(6554):541-547. doi: 10.1126/science.abi4708. Epub 2021 Jun 22.
2
Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity.发现可抑制新冠病毒感染性的抗血管紧张素转换酶2小肽
Adv Ther (Weinh). 2021 Jul;4(7):2100087. doi: 10.1002/adtp.202100087. Epub 2021 Apr 26.
3
Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.α1抗胰蛋白酶是严重急性呼吸综合征冠状病毒2引发蛋白酶TMPRSS2的一种抑制剂。
Pathog Immun. 2021 Apr 26;6(1):55-74. doi: 10.20411/pai.v6i1.408. eCollection 2021.
4
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.单剂 Ad26.COV2.S 疫苗预防新冠病毒的安全性和有效性。
N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21.
5
The SARS-CoV-2 Spike variant D614G favors an open conformational state.SARS-CoV-2 刺突变异株 D614G 有利于构象呈开放状态。
Sci Adv. 2021 Apr 16;7(16). doi: 10.1126/sciadv.abf3671. Print 2021 Apr.
6
Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.全印度新型冠状病毒SARS-CoV-2基因组学及刺突蛋白的全球多样性分析
Heliyon. 2021 Mar;7(3):e06564. doi: 10.1016/j.heliyon.2021.e06564. Epub 2021 Mar 19.
7
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.交联肽和再利用药物可抑制 SARS-CoV-2 的两种进入途径。
Nat Commun. 2021 Mar 9;12(1):1517. doi: 10.1038/s41467-021-21825-w.
8
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.α-1 抗胰蛋白酶抑制 TMPRSS2 蛋白酶活性和 SARS-CoV-2 感染。
Nat Commun. 2021 Mar 19;12(1):1726. doi: 10.1038/s41467-021-21972-0.
9
SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants.SARS-CoV-2 基因组学：对病毒变异进行测序的印度视角。
J Biosci. 2021;46(1). doi: 10.1007/s12038-021-00145-7.
10
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.一种用于 EGFR 异二聚体抑制的嫁接肽拟肽：在 NSCLC 模型中的意义。
Eur J Med Chem. 2021 Apr 15;216:113312. doi: 10.1016/j.ejmech.2021.113312. Epub 2021 Feb 23.
Zotero 插件